bosutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4359	380843-75-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: WAY-173606 bosutinib bosulif bosutinib monohydrate bosutinib hydrate SKI-606 SKI 606	a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases Molecular weight: 530.45 Formula: C26H29Cl2N5O3 CLOGP: 4.94 LIPINSKI: 1 HAC: 8 HDO: 1 TPSA: 82.88 ALOGS: -4.75 ROTB: 9 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

WAY-173606
bosutinib
bosulif
bosutinib monohydrate
bosutinib hydrate
SKI-606
SKI 606

a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases

Molecular weight: 530.45
Formula: C26H29Cl2N5O3
CLOGP: 4.94
LIPINSKI: 1
HAC: 8
HDO: 1
TPSA: 82.88
ALOGS: -4.75
ROTB: 9

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 4, 2012	FDA	WYETH PHARMS INC
Sept. 26, 2014	PMDA	Pfizer Japan Inc

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	779.50	24.81	602	5695	714764	62767961
Nausea	232.51	24.81	347	5950	854124	62628601
Neoplasm progression	178.12	24.81	82	6215	36346	63446379
Pleural effusion	131.50	24.81	93	6204	93117	63389608
Cytogenetic analysis abnormal	115.47	24.81	25	6272	895	63481830
Vomiting	100.77	24.81	190	6107	559427	62923298
Drug resistance	88.76	24.81	44	6253	22889	63459836
Philadelphia chromosome positive	85.84	24.81	17	6280	389	63482336
Rash	69.89	24.81	164	6133	560707	62922018
Blast crisis in myelogenous leukaemia	52.64	24.81	12	6285	545	63482180
Abdominal pain upper	48.42	24.81	79	6218	206365	63276360
Fatigue	46.57	24.81	192	6105	887836	62594889
Abdominal pain	41.00	24.81	90	6207	293366	63189359
Drug intolerance	36.87	24.81	89	6208	308572	63174153
Pulmonary oedema	30.19	24.81	32	6265	54841	63427884
Second primary malignancy	29.98	24.81	15	6282	7938	63474787
Cytopenia	29.95	24.81	17	6280	11584	63471141
Drug ineffective	28.88	24.81	37	6260	1044728	62437997
Death	27.04	24.81	90	6207	374291	63108434
Pericardial effusion	24.98	24.81	22	6275	30036	63452689
Haematotoxicity	24.91	24.81	14	6283	9362	63473363

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	561.16	26.10	478	5279	389434	34561740
Neoplasm progression	257.22	26.10	108	5649	23192	34927982
Pleural effusion	236.85	26.10	154	5603	81392	34869782
Drug intolerance	135.73	26.10	97	5660	59473	34891701
Cytogenetic analysis abnormal	129.92	26.10	29	5728	710	34950464
Nausea	98.51	26.10	189	5568	339719	34611455
Drug resistance	77.47	26.10	50	5707	25877	34925297
Fatigue	71.50	26.10	175	5582	370478	34580696
Second primary malignancy	59.34	26.10	28	5729	7858	34943316
Abdominal discomfort	58.46	26.10	60	5697	59775	34891399
Philadelphia chromosome positive	51.28	26.10	12	5745	364	34950810
Rash	49.07	26.10	111	5646	222641	34728533
Myopathy toxic	41.20	26.10	11	5746	575	34950599
Blast crisis in myelogenous leukaemia	40.87	26.10	11	5746	593	34950581
Acquired gene mutation	36.05	26.10	12	5745	1343	34949831
Fluid retention	31.88	26.10	30	5727	26857	34924317
Muscle disorder	28.34	26.10	12	5745	2609	34948565
Clonal evolution	27.75	26.10	6	5751	126	34951048
Vomiting	27.24	26.10	96	5661	247525	34703649

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	1174.33	23.05	950	9845	879539	78854054
Neoplasm progression	361.48	23.05	164	10631	51518	79682075
Nausea	277.28	23.05	475	10320	956721	78776872
Pleural effusion	266.56	23.05	192	10603	145070	79588523
Cytogenetic analysis abnormal	175.32	23.05	39	10756	1151	79732442
Fatigue	110.08	23.05	324	10471	929403	78804190
Vomiting	105.86	23.05	259	10536	665569	79068024
Philadelphia chromosome positive	103.76	23.05	23	10772	667	79732926
Rash	93.97	23.05	227	10568	578131	79155462
Second primary malignancy	74.04	23.05	37	10758	14313	79719280
Abdominal pain upper	70.37	23.05	116	10679	223703	79509890
Abdominal pain	56.85	23.05	147	10648	389422	79344171
Death	49.90	23.05	179	10616	566335	79167258
Drug resistance	49.56	23.05	43	10752	42170	79691423
Drug ineffective	43.07	23.05	50	10745	1080863	78652730
Acquired gene mutation	40.01	23.05	14	10781	2219	79731374
Illness	38.47	23.05	39	10756	46472	79687121
Drug intolerance	37.77	23.05	99	10696	264020	79469573
Product dose omission issue	36.64	23.05	94	10701	247443	79486150
Pulmonary oedema	36.50	23.05	52	10743	88202	79645391
Fluid retention	34.74	23.05	45	10750	69764	79663829
Blast crisis in myelogenous leukaemia	34.50	23.05	10	10785	863	79732730
Clonal evolution	30.88	23.05	7	10788	225	79733368
Toxicity to various agents	29.75	23.05	10	10785	421530	79312063
Bone pain	29.41	23.05	37	10758	55705	79677888
Myopathy toxic	28.08	23.05	9	10786	1089	79732504
Abdominal discomfort	27.10	23.05	85	10710	250642	79482951
Pericardial effusion	24.89	23.05	31	10764	46206	79687387
Constipation	24.44	23.05	89	10706	282961	79450632
Cytopenia	24.40	23.05	21	10774	20362	79713231

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EA04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors
FDA MoA	N0000020009	Bcr-Abl Tyrosine Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Blastic phase chronic myeloid leukemia	indication	413656006
Chronic Myelocytic Leukemia Accelerated Phase	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	6.69	Basic
pKa3	4.74	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	7417148	Dec. 11, 2025	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 400MG BASE	BOSULIF	PF PRISM CV	N203341	Oct. 27, 2017	RX	TABLET	ORAL	7417148	Dec. 11, 2025	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 500MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	7417148	Dec. 11, 2025	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 100MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 100MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 400MG BASE	BOSULIF	PF PRISM CV	N203341	Oct. 27, 2017	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 400MG BASE	BOSULIF	PF PRISM CV	N203341	Oct. 27, 2017	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 500MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 500MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	11103497	Feb. 28, 2034	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	Dec. 19, 2024	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
EQ 400MG BASE	BOSULIF	PF PRISM CV	N203341	Oct. 27, 2017	RX	TABLET	ORAL	Dec. 19, 2024	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
EQ 500MG BASE	BOSULIF	PF PRISM CV	N203341	Sept. 4, 2012	RX	TABLET	ORAL	Dec. 19, 2024	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN	INHIBITOR	Kd	8.38	CHEMBL	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN	INHIBITOR	Kd	9	CHEMBL	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN	INHIBITOR	Kd	8.47	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN	INHIBITOR	Kd	10.54	CHEMBL	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	7.14	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		Kd	7.74	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	9.23	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN		Kd	8.40	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	7.96	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN		Kd	7.74	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	6	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	5.42	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	6.42	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	5.29	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		Kd	5.60	CHEMBL
Ribosomal protein S6 kinase alpha-3	Kinase	P51812	KS6A3_HUMAN		Kd	5.92	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	5.89	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	6.31	CHEMBL
Rho-associated protein kinase 1	Kinase	Q13464	ROCK1_HUMAN		Kd	6.06	CHEMBL
Focal adhesion kinase 1	Kinase	Q05397	FAK1_HUMAN		Kd	6.24	CHEMBL
Serine/threonine-protein kinase PLK1	Kinase	P53350	PLK1_HUMAN		Kd	5.74	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN		Kd	7.59	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	5.51	CHEMBL
Protein kinase C delta type	Kinase	Q05655	KPCD_HUMAN		Kd	5.80	CHEMBL
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN		Kd	5.96	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	6.44	CHEMBL
Tyrosine-protein kinase SYK	Kinase	P43405	KSYK_HUMAN		Kd	6.54	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	7.49	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN		Kd	5.41	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN		Kd	8.05	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Kinase	Q13555	KCC2G_HUMAN		Kd	5.44	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	5.64	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.66	CHEMBL
Cytoplasmic tyrosine-protein kinase BMX	Kinase	P51813	BMX_HUMAN		Kd	6.70	CHEMBL
Serine/threonine-protein kinase Nek2	Kinase	P51955	NEK2_HUMAN		Kd	5.80	CHEMBL
Ribosomal protein S6 kinase alpha-2	Kinase	Q15349	KS6A2_HUMAN		Kd	5.49	CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1	Kinase	Q13131	AAPK1_HUMAN		Kd	5.41	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	6.47	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Kinase	Q9UQM7	KCC2A_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	8.15	CHEMBL
Tyrosine-protein kinase Fer	Kinase	P16591	FER_HUMAN		Kd	6.44	CHEMBL
Protein kinase C epsilon type	Kinase	Q02156	KPCE_HUMAN		Kd	5.62	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	8.82	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN		Kd	7.57	CHEMBL
Ephrin type-A receptor 4	Kinase	P54764	EPHA4_HUMAN		Kd	7.74	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	5.54	CHEMBL
Protein kinase C theta type	Kinase	Q04759	KPCT_HUMAN		Kd	6.04	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	5.96	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	7.51	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	6.96	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	8.20	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	6.16	CHEMBL
Serine/threonine-protein kinase 36	Kinase	Q9NRP7	STK36_HUMAN		Kd	6.24	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	8.24	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	6.46	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	8.85	CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	6.22	CHEMBL
Dual specificity protein kinase CLK2	Kinase	P49760	CLK2_HUMAN		Kd	5.77	CHEMBL
Dual specificity protein kinase CLK3	Kinase	P49761	CLK3_HUMAN		Kd	6.52	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	9.30	CHEMBL
Mitogen-activated protein kinase kinase kinase 4	Kinase	Q9Y6R4	M3K4_HUMAN		Kd	6.96	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	8.89	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5.43	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	7.48	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D	Kinase	Q8IU85	KCC1D_HUMAN		Kd	6.26	CHEMBL
Cyclin-dependent kinase 16	Kinase	Q00536	CDK16_HUMAN		Kd	5.62	CHEMBL
Serine/threonine-protein kinase 4	Kinase	Q13043	STK4_HUMAN		Kd	6.72	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	7.54	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	8.33	CHEMBL
Dual specificity protein kinase CLK4	Kinase	Q9HAZ1	CLK4_HUMAN		Kd	5.49	CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2	Kinase	Q96RR4	KKCC2_HUMAN		Kd	6.11	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	6.92	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	8.04	CHEMBL
Testis-specific serine/threonine-protein kinase 1	Kinase	Q9BXA7	TSSK1_HUMAN		Kd	5.34	CHEMBL
Cyclin-dependent kinase 15	Kinase	Q96Q40	CDK15_HUMAN		Kd	5.80	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 7	Kinase	O14733	MP2K7_HUMAN		Kd	5.28	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	7.72	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	8	CHEMBL
Tyrosine-protein kinase ITK/TSK	Kinase	Q08881	ITK_HUMAN		Kd	5.77	CHEMBL
Tyrosine-protein kinase ZAP-70	Kinase	P43403	ZAP70_HUMAN		Kd	5.80	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		Kd	8.32	CHEMBL
Tyrosine-protein kinase Tec	Kinase	P42680	TEC_HUMAN		Kd	5.49	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	7.28	CHEMBL
BDNF/NT-3 growth factors receptor	Kinase	Q16620	NTRK2_HUMAN		Kd	5.92	CHEMBL
Tyrosine-protein kinase receptor TYRO3	Kinase	Q06418	TYRO3_HUMAN		Kd	7.21	CHEMBL
Ephrin type-B receptor 2	Kinase	P29323	EPHB2_HUMAN		Kd	8.08	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	5.92	CHEMBL
Ribosomal protein S6 kinase beta-1	Kinase	P23443	KS6B1_HUMAN		Kd	6.18	CHEMBL
Serine/threonine-protein kinase N2	Kinase	Q16513	PKN2_HUMAN		Kd	5.49	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	5.27	CHEMBL
Serine/threonine-protein kinase 3	Kinase	Q13188	STK3_HUMAN		Kd	6.43	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	5.57	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	6.66	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase Chk1	Kinase	O14757	CHK1_HUMAN		Kd	5.52	CHEMBL
Serine/threonine-protein kinase PAK 3	Kinase	O75914	PAK3_HUMAN		Kd	5.24	CHEMBL
Cyclin-dependent kinase 14	Kinase	O94921	CDK14_HUMAN		Kd	5.85	CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	Kinase	Q99755	PI51A_HUMAN		Kd	5.48	CHEMBL
Wee1-like protein kinase	Kinase	P30291	WEE1_HUMAN		Kd	6.29	CHEMBL
Serine/threonine-protein kinase 25	Kinase	O00506	STK25_HUMAN		Kd	6.05	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	7.10	CHEMBL
Protein-tyrosine kinase 2-beta	Kinase	Q14289	FAK2_HUMAN		Kd	6.41	CHEMBL
Serine/threonine-protein kinase RIO1	Kinase	Q9BRS2	RIOK1_HUMAN		Kd	5.66	CHEMBL
Casein kinase I isoform alpha-like	Kinase	Q8N752	KC1AL_HUMAN		Kd	5.59	CHEMBL
Casein kinase I isoform delta	Kinase	P48730	KC1D_HUMAN		Kd	6.62	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	5.54	CHEMBL
Serine/threonine-protein kinase tousled-like 1	Kinase	Q9UKI8	TLK1_HUMAN		Kd	6.24	CHEMBL
Serine/threonine-protein kinase tousled-like 2	Kinase	Q86UE8	TLK2_HUMAN		Kd	5.68	CHEMBL
NT-3 growth factor receptor	Kinase	Q16288	NTRK3_HUMAN		Kd	5.47	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	7.14	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Kinase	Q14164	IKKE_HUMAN		Kd	7.28	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3	Kinase	P46734	MP2K3_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase 26	Kinase	Q9P289	STK26_HUMAN		Kd	7.43	CHEMBL
Serine/threonine-protein kinase NLK	Kinase	Q9UBE8	NLK_HUMAN		Kd	5.66	CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4	Kinase	Q9P2K8	E2AK4_HUMAN		Kd	6.57	CHEMBL
Serine/threonine-protein kinase RIO3	Kinase	O14730	RIOK3_HUMAN		Kd	5.80	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	7.54	CHEMBL
Serine/threonine-protein kinase 33	Kinase	Q9BYT3	STK33_HUMAN		Kd	7.43	CHEMBL
Serine/threonine-protein kinase TNNI3K	Kinase	Q59H18	TNI3K_HUMAN		Kd	6.77	CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1	Kinase	Q8NFD2	ANKK1_HUMAN		Kd	5.68	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.85	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	7.04	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	5.52	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	7.82	CHEMBL
NUAK family SNF1-like kinase 1	Kinase	O60285	NUAK1_HUMAN		Kd	5.23	CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Kinase	Q99640	PMYT1_HUMAN		Kd	6.46	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	8.29	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	8.48	CHEMBL
Bone morphogenetic protein receptor type-2	Kinase	Q13873	BMPR2_HUMAN		Kd	6.24	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	8.09	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	5.59	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6	Kinase	P52564	MP2K6_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	6.96	CHEMBL
Mitogen-activated protein kinase kinase kinase 9	Kinase	P80192	M3K9_HUMAN		Kd	5.57	CHEMBL
Mitogen-activated protein kinase kinase kinase 11	Kinase	Q16584	M3K11_HUMAN		Kd	5.57	CHEMBL
Serine/threonine-protein kinase 24	Kinase	Q9Y6E0	STK24_HUMAN		Kd	6.42	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.62	CHEMBL
Myosin-IIIa	Kinase	Q8NEV4	MYO3A_HUMAN		Kd	5.21	CHEMBL
Myosin-IIIb	Kinase	Q8WXR4	MYO3B_HUMAN		Kd	5.64	CHEMBL
Serine/threonine-protein kinase PAK 1	Kinase	Q13153	PAK1_HUMAN		Kd	5.64	CHEMBL
Serine/threonine-protein kinase PAK 2	Kinase	Q13177	PAK2_HUMAN		Kd	5.72	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	7.52	CHEMBL
Tyrosine-protein kinase Srms	Kinase	Q9H3Y6	SRMS_HUMAN		Kd	7	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.64	CHEMBL
Ephrin type-B receptor 3	Kinase	P54753	EPHB3_HUMAN		Kd	6.68	CHEMBL
Mitogen-activated protein kinase 7	Kinase	Q13164	MK07_HUMAN		Kd	5.64	CHEMBL
Serine/threonine-protein kinase D3	Kinase	O94806	KPCD3_HUMAN		Kd	5.34	CHEMBL
Tyrosine-protein kinase Fes/Fps	Kinase	P07332	FES_HUMAN		Kd	6.48	CHEMBL
Casein kinase I isoform alpha	Kinase	P48729	KC1A_HUMAN		Kd	6.55	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	8.51	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	8.49	CHEMBL
Serine/threonine-protein kinase TBK1	Kinase	Q9UHD2	TBK1_HUMAN		Kd	6.60	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	6.44	CHEMBL
Serine/threonine-protein kinase Chk2	Kinase	O96017	CHK2_HUMAN		Kd	6.92	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.52	CHEMBL
G protein-coupled receptor kinase 4	Kinase	P32298	GRK4_HUMAN		Kd	5.31	CHEMBL
G protein-coupled receptor kinase 7	Kinase	Q8WTQ7	GRK7_HUMAN		Kd	5.77	CHEMBL
Homeodomain-interacting protein kinase 2	Kinase	Q9H2X6	HIPK2_HUMAN		Kd	5.72	CHEMBL
Homeodomain-interacting protein kinase 3	Kinase	Q9H422	HIPK3_HUMAN		Kd	5.49	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	6.89	CHEMBL
Hormonally up-regulated neu tumor-associated kinase	Kinase	P57058	HUNK_HUMAN		Kd	5.30	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.22	CHEMBL
Mitogen-activated protein kinase kinase kinase 13	Kinase	O43283	M3K13_HUMAN		Kd	6.32	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	7.52	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	7.27	CHEMBL
Microtubule-associated serine/threonine-protein kinase 1	Kinase	Q9Y2H9	MAST1_HUMAN		Kd	6.46	CHEMBL
Serine/threonine-protein kinase NIM1	Kinase	Q8IY84	NIM1_HUMAN		Kd	5.82	CHEMBL
SRSF protein kinase 3	Kinase	Q9UPE1	SRPK3_HUMAN		Kd	5.41	CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase	Kinase	Q9UEW8	STK39_HUMAN		Kd	5.43	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	7	CHEMBL
Serine/threonine-protein kinase TAO1	Kinase	Q7L7X3	TAOK1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	6.47	CHEMBL
Serine/threonine-protein kinase ULK1	Kinase	O75385	ULK1_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase ULK2	Kinase	Q8IYT8	ULK2_HUMAN		Kd	6.35	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	6.34	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	7.80	CHEMBL
Homeodomain-interacting protein kinase 1	Kinase	Q86Z02	HIPK1_HUMAN		Kd	6.28	CHEMBL
Serine/threonine-protein kinase PLK2	Kinase	Q9NYY3	PLK2_HUMAN		Kd	6.02	CHEMBL
Serine/threonine-protein kinase 35	Kinase	Q8TDR2	STK35_HUMAN		Kd	8.70	CHEMBL
Megakaryocyte-associated tyrosine-protein kinase	Kinase	P42679	MATK_HUMAN		Kd	5.24	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	9.11	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.36	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	7.19	CHEMBL
Wee1-like protein kinase 2	Kinase	P0C1S8	WEE2_HUMAN		Kd	7.03	CHEMBL
Serine/threonine-protein kinase 32A	Kinase	Q8WU08	ST32A_HUMAN		Kd	5.74	CHEMBL
Peripheral plasma membrane protein CASK	Kinase	O14936	CSKP_HUMAN		Kd	6.08	CHEMBL
Serine/threonine-protein kinase VRK2	Kinase	Q86Y07	VRK2_HUMAN		Kd	6.15	CHEMBL
Mitogen-activated protein kinase kinase kinase 12	Kinase	Q12852	M3K12_HUMAN		Kd	6.17	CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 1	Kinase	Q9BQI3	E2AK1_HUMAN		Kd	6.20	CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	5.72	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	8.09	CHEMBL
Serine/threonine-protein kinase Nek11	Kinase	Q8NG66	NEK11_HUMAN		Kd	6.19	CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2	Kinase	Q5S007	LRRK2_HUMAN		Kd	6.30	CHEMBL
Dual serine/threonine and tyrosine protein kinase	Kinase	Q6XUX3	DUSTY_HUMAN		Kd	6.42	CHEMBL
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)	Kinase	P06748 Q9UM73	NPM_HUMAN ALK_HUMAN		IC50	6.82	CHEMBL
Tyrosine-protein kinase ABL	Kinase	P00519 P42684	ABL1_HUMAN ABL2_HUMAN		IC50	8.96	CHEMBL
Bcr/Abl fusion protein	Kinase	P00519 P11274	ABL1_HUMAN BCR_HUMAN		IC50	7.70	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	5.92	CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	5.87	CHEMBL
Macrophage-stimulating protein receptor	Kinase	Q04912	RON_HUMAN		Kd	5.20	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.70	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		Kd	6.70	CHEMBL
Tyrosine-protein kinase Blk	Kinase		BLK_MOUSE		IC50	8.14	CHEMBL
Serine/threonine-protein kinase PknB	Kinase		PKNB_MYCTU		Kd	5.26	CHEMBL

External reference:

ID	Source
4031718	VUID
N0000185728	NUI
D03252	KEGG_DRUG
918639-08-4	SECONDARY_CAS_RN
4031718	VANDF
C1831731	UMLSCUI
CHEBI:39112	CHEBI
DB8	PDB_CHEM_ID
CHEMBL288441	ChEMBL_ID
DB06616	DRUGBANK_ID
C471992	MESH_SUPPLEMENTAL_RECORD_UI
5710	IUPHAR_LIGAND_ID
8715	INN_ID
5018V4AEZ0	UNII
5328940	PUBCHEM_CID
1307619	RXNORM
192772	MMSL
28803	MMSL
d07901	MMSL
014636	NDDF
703128001	SNOMEDCT_US
703585009	SNOMEDCT_US
703586005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0135	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0135	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0136	TABLET, FILM COATED	500 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0136	TABLET, FILM COATED	500 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0193	TABLET, FILM COATED	400 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0193	TABLET, FILM COATED	400 mg	ORAL	NDA	33 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	63539-117	TABLET, FILM COATED	100 mg	ORAL	NDA	35 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	63539-117	TABLET, FILM COATED	100 mg	ORAL	NDA	35 sections
BOSULIF	HUMAN PRESCRIPTION DRUG LABEL	1	63539-193	TABLET, FILM COATED	400 mg	ORAL	NDA	35 sections